A Phase 3 interventional study of Sodium Zirconium Cyclosilicate in Hyperkalemia, sponsored by ZS Pharma, Inc.. Completed at 49 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-08-15.
Sponsored by ZS Pharma, Inc. (part of AstraZeneca) · Phase 3, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies testing sodium zirconium cyclosilicate in Hyperkalemia — 3 open to participants now, 4 under way, none of them phase 3. sodium zirconium cyclosilicate · Hyperkalemia.
Among the 27 studies testing sodium zirconium cyclosilicate in Hyperkalemia, this one is the 12th largest by enrollment, is one of 3 that started in 2014, is one of 12 in phase 3, and was the 2nd registered.
134 studies on the registry are indexed under Hyperkalemia; 26 are open to participants now.
Browse Hyperkalemia studies →3 of the 27 studies testing sodium zirconium cyclosilicate in Hyperkalemia are open now, in 2 countries. Recruiting first, the newest first:
AstraZeneca · Sites in India
Ages 18+
Leiden University Medical Center · Sites in Netherlands
Ages 18+
Qianfoshan Hospital
Ages 18–75
By country, each count listing its studies:
sodium zirconium cyclosilicate: first FDA approval 2018 (LOKELMA), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 16 Hyperkalemia studies recruiting now, 11 (69%) set no upper age limit and 2 (13%) stop at 75 or younger; 2 take children under 18; none take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 5 · Phase 3 13 · Phase 4 6
First in 2014; this study’s year is marked. 3 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 123 is above the median of 88 across 103 interventional studies indexed under Hyperkalemia.
Median enrollment 120 across the 27 interventional studies. Of the 22 that completed or were terminated, 18 (82%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 27 have an industry lead sponsor. The 10 most frequent:
This study is registered under ZS Pharma, Inc., one of the names counted as AstraZeneca. Under that name alone:
ZS Pharma, Inc. is the lead sponsor of 8 studies on the registry; none are open to participants now.
39 studies in Hyperkalemia by AstraZeneca: 2 open now, 3 under way, 1 of them phase 3. Of 36 finished, 22 (61%) have results posted.
Among the 39 studies in Hyperkalemia by AstraZeneca, this one is the 16th largest by enrollment of the 25 interventional ones that give a count, is one of 3 that started in 2014, is one of 13 in phase 3, and was the 5th registered.
AstraZeneca’s Hyperkalemia studies by the year they started, since 2011.
2 of the studies testing sodium zirconium cyclosilicate in Hyperkalemia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06736184Qianfoshan HospitalThe Cardioprotective Effects of Improving Potassium Variability in Maintenance Hemodialysis Patients | 2026-12-31 |
| NCT07944378AstraZenecaA Study Evaluating the Safety and Effectiveness of Lokelma in Indian Patients With Hyperkalaemia | 2027-10-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 27 studies testing sodium zirconium cyclosilicate in Hyperkalemia, from their registry updates:
Among AstraZeneca’s 39 in Hyperkalemia:
This tab as a report to print or save as PDF → With an account.
Subjects who completed the Double-blind Randomized Maintenance Phase (DBRMP) Study Day 29 visit in ZS-004 (NCT 02088073) and have an i-STAT potassium value that is 3.5 to 6.2 mmol/l inclusive or who discontinued during ZS-004 due to hypo- or hyperkalemia in the DBRMP and have a mean i-STAT potassium value from two consecutive measurements at 0 and 60 minutes on Acute Phase Day 1/Maintenance Phase Day 1 that is 3.5 to 6.2 mmol/l inclusive may have the option to participate in ZS-004E (NCT 021070920). Subjects who discontinued from study ZS-004 due to any other reasons (e.g. adverse events, poor compliance, investigator decision) will not be entered into study ZS-004E. All subjects who continue into the extension study must begin dosing within two (2) days after the last dose of investigational product in ZS-004.
All subjects with i-STAT potassium values between 3.5-5.5 mmol/l, inclusive at the ZS-004 (NCT 02088073) DBRMP Study Day 29 visit, who continue directly into the open-label extension study ZS-004E (NCT 021070920), will enter the Maintenance Phase (MP) and start on open-label ZS at a dose of 10g qd. All subjects with i-STAT potassium values > 5.5 mmol/l at the ZS-004 DBRMP Study Day 29 visit will undergo an acute treatment phase (AP) where they will receive ZS 10g three times a day (tid) for 24 (3 doses) or 48 hours (6 doses). If the subject's i-STAT potassium is between 3.5-5.0 mmol/l, inclusive after 24 (AP Study Day 2) or 48 hours (AP Study Day 3), the subject will enter the MP at a starting dose of 10g qd.
For subjects who discontinued during ZS-004 DBRMP due to hypo- or hyperkalemia baseline potassium values will be determined within 1 day of administration of the first dose in the ZS-004E extension study by taking two (2) consecutive i-STAT potassium measurements at 0 and 60 minutes (± 10 minutes). If the mean i-STAT value is between 3.5 - 5.5 mmol/l, inclusive, the subject will enter directly into the MP and receive 10g ZS qd; if the mean i-STAT potassium value is > 5.5 mmol/l, the subject will enter the AP. If i-STAT potassium values are still >5.0 mmol/l on the morning of AP Study Day 3, subjects will not enter the MP but will be referred to their normal health care provider for standard of care.
If the i-STAT potassium value increases above 5.5 mmol/l during the MP with treatment at 10g qd, the dose can be increased to15g qd. Conversely, if S-K decreases to between 3.0-3.4 mmol/l, inclusive, the dose of ZS can be decreased in 5g qd, decrements. If a subject is on a 5g qd dose and still develops blood potassium i-STAT values between 3.0 - 3.4mmol, inclusive the dose can be reduced to 5g every other day.
Subjects will receive up to 11 months of treatment with open-label ZS.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Open label oral administration of sodium zirconium cyclosilicate 10g once daily for 11 months.
Drug: Sodium Zirconium Cyclosilicate
Oral 10g once daily with breakfast for 11 months.
Also known as: ZS
Proportion of Subjects With Average Serum Potassium Values ≤ 5.1 mmol/L
The proportions of subjects with average serum potassium (S-K) values ≤ 5.1 mmol/L during Extended Dosing Study Days 8 to 337, inclusive
Time frame: 11 months
Proportion of Subjects With Average Serum Potassium Values ≤ 5.5 mmol/L
The proportions of subjects with average S-K values ≤ 5.5 mmol/L during Extended Dosing Study Days 8 to 337, inclusive
Time frame: 11 months
Participants took part in the study at 30 outpatient sites in the United States, Australia and South Africa from 10 May 2014 to 14 July 2015.
| Milestone | Extended Dosing Phase: ZS (Sodium Zirconium Cyclosilicate) QD |
|---|---|
| Started | 123 |
| Completed | 79 |
| Not completed | 44 |
| Withdrew: Miscellaneous | 3 |
| Withdrew: Subject compliance | 3 |
| Withdrew: Hypo-or hyperkalemia | 2 |
| Withdrew: Met ecg withdrawal criteria | 3 |
| Withdrew: Physician decision | 3 |
| Withdrew: Lost to follow-up | 2 |
| Withdrew: Withdrawal by subject | 9 |
| Withdrew: Adverse event | 7 |
| Withdrew: Expected progression of ckd | 12 |
The proportions of subjects with average serum potassium (S-K) values ≤ 5.1 mmol/L during Extended Dosing Study Days 8 to 337, inclusive
| Proportion of Participants | Extended Dosing Phase: ZS (Sodium Zirconium Cyclosilicate) QD |
|---|---|
| ED Study Day 8 | 0.875 (0.802 to 0.928) |
| ED Study Day 15 | 0.822 (0.741 to 0.886) |
| ED Study Day 22 | 0.797 (0.713 to 0.865) |
| ED Study Day 29 | 0.862 (0.786 to 0.919) |
| ED Study Day 36 | 0.848 (0.768 to 0.909) |
| ED Study Day 43 | 0.793 (0.705 to 0.864) |
| ED Study Day 50 | 0.796 (0.708 to 0.868) |
| ED Study Day 57 | 0.766 (0.675 to 0.843) |
| ED Study Day 85 | 0.807 (0.709 to 0.833) |
| ED Study Day 113 | 0.798 (0.696 to 0.877) |
| ED Study Day 141 | 0.815 (0.713 to 0.892) |
| ED Study Day 169 | 0.771 (0.656 to 0.863) |
| ED Study Day 197 | 0.809 (0.695 to 0.894) |
| ED Day Study 225 | 0.846 (0.735 to 0.924) |
| ED Study Day 253 | 0.778 (0.655 to 0.873) |
| ED Study Day 281 | 0.833 (0.715 to 0.917) |
| ED Study Day 309 | 0.828 (0.706 to 0.914) |
| ED Study Day 337 | 0.843 (0.714 to 0.930) |
| ED Study Day 337/Exit | 0.783 (0.699 to 0.853) |
| ED Study Days 8-337 Average | 0.883 (0.812 to 0.935) |
The proportions of subjects with average S-K values ≤ 5.5 mmol/L during Extended Dosing Study Days 8 to 337, inclusive
| Proportion of Participants | Extended Dosing Phase: ZS (Sodium Zirconium Cyclosilicate) QD |
|---|---|
| ED Study Day 8 | 0.950 (0.894 to 0.981) |
| ED Study Day 15 | 0.932 (0.871 to 0.970) |
| ED Study Day 22 | 0.975 (0.927 to 0.995) |
| ED Study Day 29 | 0.957 (0.902 to 0.986) |
| ED Study Day 36 | 0.955 (0.899 to 0.985) |
| ED Study Day 43 | 0.946 (0.886 to 0.980) |
| ED Study Day 50 | 0.935 (0.871 to 0.974) |
| ED Study Day 57 | 0.944 (0.882 to 0.979) |
| ED Study Day 85 | 0.943 (0.872 to 0.981) |
| ED Study Day 113 | 0.940 (0.867 to 0.980) |
| ED Study Day 141 | 0.938 (0.862 to 0.980) |
| ED Study Day 169 | 0.929 (0.841 to 0.976) |
| ED Study Day 197 | 0.941 (0.856 to 0.984) |
| ED Day Study 225 | 0.985 (0.917 to 1.000) |
| ED Study Day 253 | 0.937 (0.845 to 0.982) |
| ED Study Day 281 | 0.950 (0.861 to 0.990) |
| ED Study Day 309 | 0.914 (0.810 to 0.971) |
| ED Study Day 337 | 0.980 (0.896 to 1.000) |
| ED Study Day 337/Exit | 0.942 (0.884 to 0.976) |
| ED Study Days 8-337 Average | 1.000 (0.970 to 1.000) |
Collected over Eleven months. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| ZS (Sodium Zirconium Cyclosilicate) QD Extended Phase Dosing | — | 24/123 (19.5%) | 82/123 (66.7%) |
| Event | ZS (Sodium Zirconium Cyclosilicate) QD Extended Phase Dosing |
|---|---|
| Cardiac failure congestiveCardiac disorders | 2/123 |
| Abdominal PainGastrointestinal disorders | 2/123 |
| PneumoniaInfections and infestations | 2/123 |
| Urinary tract infectionInfections and infestations | 2/123 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 2/123 |
| AnaemiaBlood and lymphatic system disorders | 1/123 |
| Acute myocardial infarctionCardiac disorders | 1/123 |
| Cardiac failureCardiac disorders | 1/123 |
| Myocardial infarctionCardiac disorders | 1/123 |
| Retinal artery occlusionEye disorders | 1/123 |
| Event | ZS (Sodium Zirconium Cyclosilicate) QD Extended Phase Dosing |
|---|---|
| HypertensionVascular disorders | 15/123 |
| Urinary tract infectionInfections and infestations | 11/123 |
| Oedema peripheralGeneral disorders | 10/123 |
| ConstipationGastrointestinal disorders | 7/123 |
| AnaemiaBlood and lymphatic system disorders | 6/123 |
| Muscle spasmsMusculoskeletal and connective tissue disorders | 6/123 |
| Upper respiratory tract infectionInfections and infestations | 5/123 |
| DiarrhoeaGastrointestinal disorders | 4/123 |
| NauseaGastrointestinal disorders | 4/123 |
| VomitingGastrointestinal disorders | 4/123 |
2 subjects did not have any S-K measurements during the ED phase due to early termination and are excluded from baseline characteristics
| Age, Continuous(Years) | Extended Dosing Phase: ZS (Sodium Zirconium Cyclosilicate) QD |
|---|---|
| Mean | 63.7 ± 12.29 |
| Sex: Female, Male(Participants) | Extended Dosing Phase: ZS (Sodium Zirconium Cyclosilicate) QD |
|---|---|
| Female | 51 |
| Male | 70 |
| Race/Ethnicity, Customized(Participants) | Extended Dosing Phase: ZS (Sodium Zirconium Cyclosilicate) QD |
|---|---|
| Asian | 2 |
| Black or African American | 11 |
| White | 107 |
| Other | 1 |
| Study ZS-004 Acute Phase S-K baseline(Participants) | Extended Dosing Phase: ZS (Sodium Zirconium Cyclosilicate) QD |
|---|---|
| < 5.5 mmol/L | 54 |
| 5.5-< 6.0 mmol/L | 53 |
| ≥ 6.0 mmol/L | 14 |
| Acute Phase eGFR at baseline(Participants) | Extended Dosing Phase: ZS (Sodium Zirconium Cyclosilicate) QD |
|---|---|
| <60 mL/min | 90 |
| ≥ 60 mL/min | 31 |
| Cormordid conditions and concomitant medications which may contirubute to hyperkalemia(Participants) | Extended Dosing Phase: ZS (Sodium Zirconium Cyclosilicate) QD |
|---|---|
| RAAS inhibitor medication | 83 |
| Diabetes mellitus | 80 |
| Chronic kidney disease | 76 |
| Heart failure | 50 |
Ran from May 2014 to primary completion in Jul 2015, 14 months.
Results were first posted in Aug 2018, 3 years after primary completion. A results delay was requested in Nov 2015.
Of 18 phase 3 interventional studies under Hyperkalemia, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 29. This study's 14 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sodium zirconium cyclosilicate